Advertisement

Acta Diabetologica

, Volume 55, Issue 7, pp 759–761 | Cite as

Empagliflozin, metformin and insulin degludec, during pregnancy: a case report

  • G. Formoso
  • F. Ginestra
  • G. Di Dalmazi
  • A. Consoli
Case Report

Introduction

In the last 10 years, several new oral hypoglycemic agents and novel insulin analogs have been introduced for type 2 diabetes therapy which demonstrated to be a valid and safety support in terms of blood glucose and weight control as well as cardiovascular protection. Among them, empagliflozin, by inhibiting the sodium-glucose co-transporter 2 (SGLT-2) at the proximal convoluted tubule level, decreases renal glucose reabsorption and favors calories loss. Insulin degludec is an extra-long-acting insulin analog associated with reduced glycemic variability and reduced hypoglycemic events as compared to glargine. Metformin, in use since many years for diabetes treatment, is a biguanide lowering blood glucose by reducing hepatic glucose output, increasing insulin sensitivity and enhancing peripheral glucose uptake. In Italy, none of these drugs is approved for use during pregnancy.

In animal studies, empagliflozin treatment has shown no direct or indirect detrimental effects on...

Keywords

Pregnancy Diabetes Therapy Metformin Empagliflozin Degludec 

Notes

Compliance with ethical standards

Conflict of interest

A.C. has received speaker fees and/or consulting honoraria from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche Diagnostics, Sanofi-Aventis, Takeda and has received research grant support from Eli Lilly and Novo Nordisk. G.F. has received speaker fees from Eli Lilly, Merck Sharp & Dohme, Menarini Diagnostics and Servier. F.G. and G.D.D. have received nothing.

Ethical approval

The study was in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments.

Informed consent

Informed consent was obtained from the patient included in the case report.

References

  1. 1.
    Marso SP, McGuire DK, Zinman B et al (2017) Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 377:723–732.  https://doi.org/10.1056/NEJMoa1615692 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Simmons D (2010) Metformin treatment for TYPE 2 diabetes in pregnancy? Best Pract Res Clin Endocrinol Metab 24:625–634.  https://doi.org/10.1016/j.beem.2010.05.002 CrossRefPubMedGoogle Scholar
  3. 3.
    Zinman B, Marso SP, Poulter NR et al (2018) Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia 61:48–57.  https://doi.org/10.1007/s00125-017-4423-z CrossRefPubMedGoogle Scholar
  4. 4.
  5. 5.
    Milluzzo A, Tumminia A, Scalisi NM, Frittitta L, Vigneri R, Sciacca L (2017) Insulin degludec in the first trimester of pregnancy: report of two cases. J Diabetes Investig.  https://doi.org/10.1111/jdi.12721 PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Medicine and Aging Sciences, Aging and Translational Medicine Research Center (CeSI-Met)G. d’Annunzio UniversityChietiItaly

Personalised recommendations